Home > Boards > US OTC > Food - Processing and Agriculture > Mydecine Innovations Group Inc. (MYCOF)

News is out on this here is the

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Finditdotcom Member Profile
Followed By 0
Posts 228
Boards Moderated 0
Alias Born 03/03/16
160x600 placeholder
Finditdotcom   Saturday, 06/27/20 09:40:01 PM
Re: None
Post # of 960 
News is out on this here is the release from OTC Tip Reporter. THIS IS NOT THE COMPLETE RELEASE CLICK ON LINK FOR ENTIRE RELEASE


OTC TIP REPORTER Covers Mydecine OTC MYCOF Drops Bombshell Acquisition News Their Acquiring Mindleap Health’s Advanced Digital Telehealth Platform
Immediately turn your attention to Mydecine Innovations Group (MYCOF)
Saint Cloud 6/28/2020 12:55:43 AM

OTC Tip Reporter releases next company we are covering and its Mydecine (OTC Stock Symbol MYCOF). This is my next stock that looks ready to move in a major way, so make sure you have it pulled up on your trading screen Monday morning at the opening bell.

Mydecine Innovations Group is a life sciences company dedicated to the development and commercialization of adaptive pathway medicines, natural health products and digital health solutions.

Mydecine experienced cross functional teams have the capabilities to oversee all areas of drug development including synthesis, drug delivery system development, clinical trial execution, through to product commercialization and marketing.

By leveraging strategic partnerships with scientific, medical, military, and clinical organizations Mydecine is at the forefront of the efficient development of psychedelic derived medicines and therapeutic solutions.

Their trailblazing portfolio of companies is focused on providing innovative and effective treatment options that can help millions of people live healthier lives.

Mydecine Innovations Group Inc. is a parent company which operates innovative product divisions in the Naturally Sourced Therapies (NST) space.

Mydecine Innovations Group Inc. operates a number of hemp-derived CBD and psilocybin brands that design, manufacture and distribute cutting edge products. Mydecine Innovations Group Inc. further enhances their portfolio with cultivation properties, land assets and retail space.

Mydecine Signs Partnership Agreement With Applied Pharmaceutical Innovation

Mydecine Innovations Group Inc. announced the establishment of a research division agreement with Applied Pharmaceutical Innovation (“API”), a translational commercial drug development institute hosted in the University of Alberta’s Faculty of Pharmacy and Pharmaceutical Sciences.

The agreement with API provides exceptional capacity for Mydecine and the ability to significantly speed their product development with leading experts in the pharmaceutical sciences and established drug development facilities.


The Faculty of Pharmacy and Pharmaceutical Sciences is consistently ranked in the top 15 globally for the citations of research by international QS rankings in pharmacy and pharmacology and includes a wide range of experts from discovery, pharmaceutical analysis, drug action, disposition, formulation and clinical development.

Mydecine is also able to access broader expertise through the agreement such as API’s collaborating institute the Alberta Machine Intelligence Institute (Amii) – ranked among the top 5 institutes in the world for AI/ML – as well as experts in mycology, pharmacometrics, neuropharmacology and much more at universities throughout the API network.

Through the agreement, Mydecine has the ability to immediately commence fungal discovery investigations with varietal mushrooms and their extracts, including scheduled substances.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist